Must Read Policy and Medicine Blog: FDA CDER Guidance Agenda for Remainder of 2014

As we continue to cover the FDA and Congress begins considering an overhaul to the FDA's regulatory framework, it might be helpful for our readers to review the previously published guidance agenda from the agency's Center for Drug Evaluation and Research. Several of these guidance's have already been released with many more expected throughout the year.  Continue to Read here